GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan Keqian Biology Co Ltd (SHSE:688526) » Definitions » Debt-to-EBITDA

Wuhan Keqian Biology Co (SHSE:688526) Debt-to-EBITDA : 0.47 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Wuhan Keqian Biology Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Wuhan Keqian Biology Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥186.3 Mil. Wuhan Keqian Biology Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥5.7 Mil. Wuhan Keqian Biology Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ¥408.1 Mil. Wuhan Keqian Biology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.47.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Wuhan Keqian Biology Co's Debt-to-EBITDA or its related term are showing as below:

SHSE:688526' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.11   Med: 0.3   Max: 0.51
Current: 0.47

During the past 8 years, the highest Debt-to-EBITDA Ratio of Wuhan Keqian Biology Co was 0.51. The lowest was 0.11. And the median was 0.30.

SHSE:688526's Debt-to-EBITDA is ranked better than
67.78% of 270 companies
in the Biotechnology industry
Industry Median: 1.31 vs SHSE:688526: 0.47

Wuhan Keqian Biology Co Debt-to-EBITDA Historical Data

The historical data trend for Wuhan Keqian Biology Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Keqian Biology Co Debt-to-EBITDA Chart

Wuhan Keqian Biology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial - 0.11 0.11 0.49 0.51

Wuhan Keqian Biology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.67 0.57 1.55 0.47

Competitive Comparison of Wuhan Keqian Biology Co's Debt-to-EBITDA

For the Biotechnology subindustry, Wuhan Keqian Biology Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Keqian Biology Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wuhan Keqian Biology Co's Debt-to-EBITDA falls into.



Wuhan Keqian Biology Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Wuhan Keqian Biology Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(287.764 + 5.745) / 580.004
=0.51

Wuhan Keqian Biology Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(186.256 + 5.675) / 408.06
=0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Wuhan Keqian Biology Co  (SHSE:688526) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Wuhan Keqian Biology Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Wuhan Keqian Biology Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Keqian Biology Co (SHSE:688526) Business Description

Traded in Other Exchanges
N/A
Address
No. 419, Gaoxin 2nd Road, Donghu New Technology Development Zone, Hubei Province, Wuhan, CHN, 430073
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
Executives
Hao Gen Xi Core technical personnel
Zhang Hua Wei Core technical personnel
Zhou Ming Guang Core technical personnel
Zou Tian Tian senior management
Xu Gao Yuan Director
Chen Guan Ping Director

Wuhan Keqian Biology Co (SHSE:688526) Headlines

No Headlines